Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
To the Editor: Linezolid is the first oxazolidinone antibiotic with labeling approved to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We report 3 cases of myelosuppression with red cell hypoplasia that occurred following therapy with linezolid. Although reversible thrombocytopenia has been reported in patients receiving more than 2 weeks of therapy,1 we found additional bone marrow changes that appear similar to those seen in reversible chloramphenicol toxicity.
Green SL, Maddox JC, Huttenbach ED. Linezolid and Reversible Myelosuppression. JAMA. 2001;285(10):1291. doi:10.1001/jama.285.10.1291